PREVIEW: Eli Lilly and Co (LLY) earnings due 03/Feb at 11:25GMT/06:25EST
Eli Lilly and Co (LLY) Q4 2021 (USD): EPS (exp. 2.46/2.93 GAAP), Revenue (exp. 7.73bln)
KEY PHARMA SALES:
- Trulicity: (exp. 1.80bln)
- Humalog: (exp. 662mln)
- Bamlanivimab/LY-COV555: (exp. 648mln)
- Taltz/Ixekizumab: (exp. 640mln)
- Alimta: (exp. 496mln)
DIVIDEND:
- Qtrly Dividend: (exp. 0.85)
- FY Dividend: (exp. 3.35)
EPS GUIDANCE:
- Q1 2021 EPS View: (exp. 2.10)
- FY 2021 EPS View: (exp. 8.52)
REVENUE GUIDANCE:
- Q1 2022 Revenue View: (exp. 6.88bln)
- FY 2022 Revenue View: (exp. 28.04bln)
INDEX WEIGHT:
- 0.6% SPX weight
- Sector/Industry: Health Care/Pharmaceuticals
BROKER RATING:
- Avg Rating: 'Buy'
- Avg Price Target: USD 285.42
- Price Target Changes (last 30 days): 3 upward vs 3 downward
02 Feb 2022 - 17:00- - Source: Newsquawk
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts